News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

QR Pharma Completes $2.4 Million Seed Financing with Round-Closing Investments from BioAdvance and Angels to Advance Clinical Development of two Alzheimer’s Disease Compounds


6/2/2010 10:26:22 AM

RADNOR, Pa.--(BUSINESS WIRE)--QR Pharma, Inc., a specialty pharmaceutical company focused on developing novel therapeutics for the treatment of Alzheimer’s disease, announced today a $500,000 investment from BioAdvance and additional funding from Angel Investors. These investments closed a total of $2.4 million seed round, which QR opened a year ago, including Ben Franklin Technology Partner’s $500,000 investment as well as other private investor funds.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES